Specialization
Focus of research
Dr Beaumont is a senior scientist at the Department of Medical Microbiology and Infection Prevention, at Amsterdam UMC, University of Amsterdam, The Netherlands. His work focusses on natural and vaccine induced humeral immune responses against HIV-1, HCV and respiratory viruses and he supervises outbreak preparedness studies on the immunogenicity of arenaviruses, Crimean-Congo hemorrhagic fever virus, Marburg virus and others. Beaumont obtained his PhD in 2002 in the laboratory of Prof. dr. Hanneke Schuitemaker at Sanquin Research, Amsterdam. He continued his work on HIV-1 induced innate and adaptive immunity as a postdoctoral fellow at the McCune Lab, Gladstone Institute, University of California at San Francisco, San Francisco. After moving back to The Netherlands in the winter of 2004 he became the first employee of the biotech startup company AIMM Therapeutics. Here he developed the B cell immortalizing technology that led to the identification of the RSV neutralizing antibody D25. In collaboration with the NIH in Washington Beaumont helped solving the conformation of the RSV pre-fusion F protein, a finding that laid the foundation for the development of RSV F protein based vaccines. D25 is now applied worldwide in the prevention of RSV infection in newborns under the brand name Beyfortus (nirsevimab).